• 原料直供
• 试剂商城
• 直接询价

分类

• {SNA} Approved Therapeutics/Drug Candidates, B, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, Non-Receptor Tyrosine Kinase Biology, Non-Receptor Tyrosine Kinase Inhibitors, Pfizer Compounds, v-Src Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog (Src)
• Inhibitors
• Heterocycles
• Pharmaceuticals
• Intermediates & Fine Chemicals
• {SNA} Approved Therapeutics/Drug Candidates, B, Bioactive Small Molecule Alphabetical Index, Diversification Ready Pharma-Developed Compounds, Kinase/Phosphatase Biology, Non-Receptor Tyrosine Kinase Biology, Non-Receptor Tyrosine Kinase Inhibitors, Pfizer Compounds, v-Src Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog (Src), 生物活性小分子, 细胞信号转导和神经科学,
• Aromati

产品应用

• Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

相关文献及参考

• ########

安全信息